165 related articles for article (PubMed ID: 30298304)
1. Effect of a new inhibitor of factor Xa zifaxaban, on thrombosis in the inferior vena cava in rabbits.
Qiu X; Zhou J; Wang W; Zhao Z; Tang L; Sun S
J Thromb Thrombolysis; 2019 Jan; 47(1):80-86. PubMed ID: 30298304
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical pharmacodynamic study of a novel oral factor Xa inhibitor zifaxaban.
Qiu X; Wang W; Zhao Z; Sun S; Tang L
Eur J Pharmacol; 2018 Oct; 836():50-56. PubMed ID: 30125563
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
[TBL] [Abstract][Full Text] [Related]
4. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
[TBL] [Abstract][Full Text] [Related]
5. Successful use of rivaroxaban in inferior vena cava thrombosis provoked by multiple traumatic injuries and surgeries: A case report.
Kido K; Noyes E; Gutnik L
J Clin Pharm Ther; 2017 Oct; 42(5):631-633. PubMed ID: 28497637
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
Perzborn E; Strassburger J; Wilmen A; Pohlmann J; Roehrig S; Schlemmer KH; Straub A
J Thromb Haemost; 2005 Mar; 3(3):514-21. PubMed ID: 15748242
[TBL] [Abstract][Full Text] [Related]
7. Reversal of anticoagulants: an overview of current developments.
Greinacher A; Thiele T; Selleng K
Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
[TBL] [Abstract][Full Text] [Related]
8. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
9. An Unusual Case of Inferior Vena Cava Thrombosis in a Healthy Male Bodybuilder.
Imanishi J; Iseri M; Motoki M; Yoshikawa S; Sone N; Honjo T; Kamemura K; Kaihotsu K; Iwahashi M
Intern Med; 2018 Sep; 57(17):2517-2521. PubMed ID: 29709932
[TBL] [Abstract][Full Text] [Related]
10. Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review.
Khadse AN; Sharma MK; Murumkar PR; Rajput SJ; Yadav MR
Mini Rev Med Chem; 2018; 18(16):1332-1353. PubMed ID: 29692238
[TBL] [Abstract][Full Text] [Related]
11. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.
Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C
Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317
[TBL] [Abstract][Full Text] [Related]
12. Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.
Fukuda T; Tsuji N; Honda Y; Kamisato C; Morishima Y; Shibano T
Thromb Haemost; 2011 Dec; 106(6):1062-8. PubMed ID: 21946952
[TBL] [Abstract][Full Text] [Related]
13. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors.
Huang C; Wang W; Li Y; Zhang S; Meng F; Xu W; Yuan J; Chen L
Oncotarget; 2017 Jun; 8(23):37186-37199. PubMed ID: 28415603
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
Meddahi S; Samama MM
J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
[TBL] [Abstract][Full Text] [Related]
16. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
[TBL] [Abstract][Full Text] [Related]
18. Contemporary medicinal-chemistry strategies for discovery of blood coagulation factor Xa inhibitors.
Hao X; Zuo X; Kang D; Zhang J; Song Y; Liu X; Zhan P
Expert Opin Drug Discov; 2019 Sep; 14(9):915-931. PubMed ID: 31172842
[No Abstract] [Full Text] [Related]
19. Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits.
Abendschein DR; Baum PK; Martin DJ; Vergona R; Post J; Rumennik G; Sullivan ME; Eisenberg PR; Light DR
J Cardiovasc Pharmacol; 2000 May; 35(5):796-805. PubMed ID: 10813384
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.
Xing J; Yang L; Yang Y; Zhao L; Wei Q; Zhang J; Zhou J; Zhang H
Eur J Med Chem; 2017 Jan; 125():411-422. PubMed ID: 27689724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
